Clinical Trial: A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07418749) titled 'A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer' on Feb. 11.

Brief Summary: The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Recurrent Cervical Cancer Metastatic Cervical Cancer

Intervention: DRUG: SHR-A2102 for Injection

SHR-A2...